Edition:
United States

Rexahn Pharmaceuticals Inc (RNN.A)

RNN.A on American Stock Exchange

0.22USD
3:49pm EST
Change (% chg)

$-0.03 (-11.16%)
Prev Close
$0.25
Open
$0.25
Day's High
$0.25
Day's Low
$0.22
Volume
151,249
Avg. Vol
178,504
52-wk High
$0.42
52-wk Low
$0.13

RNN.A

Chart for RNN.A

About

Rexahn Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company engaged in the discovery, development and commercialization of treatments for cancer. The Company's clinical-stage drug candidates in active development include Archexin, RX-3117 and Supinoxin (RX-5902). Archexin is a potent inhibitor of the protein... (more)

Overall

Beta: -0.17
Market Cap(Mil.): $59.32
Shares Outstanding(Mil.): 237.37
Dividend: --
Yield (%): --

Financials

  RNN.A Industry Sector
P/E (TTM): -- 47.00 29.32
EPS (TTM): -0.06 -- --
ROI: -57.04 -4.07 13.03
ROE: -66.58 4.71 14.17

BRIEF-Rexahn Pharmaceuticals announced update on safety, efficacy of RX-3117 in ongoing phase IIa clinical trial in metastatic pancreatic cancer

* Rexahn pharmaceuticals - announced update on safety and efficacy of rx-3117 in an ongoing phase IIa clinical trial in metastatic pancreatic cancer

Jan 20 2017

BRIEF-Rexahn Pharmaceuticals reports Q3 loss per share of $0.01

* Rexahn Pharma - expects cash, investments as of Sept 30, 2016 to be sufficient to fund cash flow requirements for activities into first half of 2018

Nov 07 2016

BRIEF-Rexahn Pharmaceuticals says received notice of allowance from U.S PTO

* Received notice of allowance from U.S PTO for a patent for claims related to synthesis of its novel anti-cancer investigational drug candidate, rx-3117 Source text for Eikon: Further company coverage:

Oct 31 2016

BRIEF-Rexahn Pharmaceuticals presents preliminary efficacy data from phase Ib/IIa trial of RX-3117, Supinoxin phase I trial

* Rexahn Pharmaceuticals presents preliminary efficacy data from phase Ib/IIa trial of RX-3117 in metastatic pancreatic cancer and supinoxin phase I trial at 2016 European Society For Medical Oncology (ESMO) congress

Oct 10 2016

BRIEF-Rexahn Pharmaceuticals announces $6 million registered direct offering

* Rexahn Pharmaceuticals -Rexahn announces $6 million registered direct offering Source text:

Sep 14 2016

More From Around the Web

Competitors

  Price Chg
GlaxoSmithKline plc (GSK.L) 1,645.50 +9.00
Merck & Co., Inc. (MRK.N) $65.58 +0.19

Earnings vs. Estimates